MARKET RADAR
SENSEX     NIFTY      Refresh

Management Interviews

Will end 2012 with higher sales, profits: Ranbaxy  

10:07 PM | 25 April

Ranbaxy managing director and chief executive Arun Sawhney told CNBC-TV18 that the pharmaceutical company would end fiscal 2012 with better sales and ...
Ranbaxy to have 30% mkt share for Lipitor: PharmAsiaNews  

08:56 AM | 01 December

Vikas Dandekar of PharmAsiaNews.com tells CNBC-TV18 that the US FDA approval for Lipitor is definitely going to be a big positive for Ranbaxy....
Lipitor is biggest catalyst to Ranbaxy's growth: Expert  

11:55 AM | 30 November

Chirag Talati, pharma analyst at Espirito Santo Securities tells CNBC-TV18 that Ranbaxy is most likely set to go ahead with the launch of the generic ...
Ranbaxy to find a new CFO  

08:26 AM | 27 January

Ranbaxy CFO, Omesh Sethi has resigned. PharmAsia News India Bureau Chief, Vikas Dandekar, speaks exclusively to CNBC-TV18’s Reema Tendulkar on the exi...
Ranbaxy's USFDA woes may end soon  

09:07 AM | 01 December

In an interview with CNBC-TV18's Shereen Bhan, PharmAsia News India bureau chief Vikas Dandekar, spoke about the road ahead for Ranbaxy....
Ranbaxy: Resolution with USFDA on the cards?  

11:40 AM | 30 November

Drugmaker Ranbaxy Laboratories Ltd has received approval from the United States Food and Drug Administration (US FDA) to sell the generic version of A...
Ranbaxy to launch Generic Aricept in US by Monday  

03:15 PM | 27 November

Ranbaxy has launched Aricept in the US market. Estimates state that the US market for this drug is around USD 3 billion....
Quit due to difference of opinion: Ranbaxy's outgoing CEO  

06:04 PM | 12 August

Ranbaxy Laboratories on Thursday said its chief executive was stepping down after just over a year in the top spot. In an interview with CNBC-TV18, At...
Ranbaxy: Strong growth plans for India this year  

05:31 PM | 25 February

In an interview with CNBC-TV18, Atul Sobti, Chief Executive Officer and Managing Director of Ranbaxy, spoke about his outlook for the company post res...
Sales degrowth mainly due to US market: Ranbaxy  

01:49 PM | 26 October

Ranbaxy Labs announced its third quarter numbers for the financial year 2009 (Q3FY09). Post company results, its Managing Director and Chief Executive...
Daiichi's role in Ranbaxy more defined now: Pharma Asia  

10:15 AM | 26 May

Vikas Dandekar of pharmasianews.com said that the 20% upsurge not expected. This act brings a lot of clarity on Daiichi’s role and that created confid...
Daiichi's role in Ranbaxy more defined now: Pharma Asia  

09:50 PM | 25 May

Vikas Dandekar of pharmasianews.com said that the 20% upsurge not expected. This act brings a lot of clarity on Daiichi’s role and that created confid...
Ranbaxy scouts for US FDA approved plant  

04:14 PM | 22 January

Malvinder Singh, CMD and CEO, Ranbaxy Laboratories, said mark-to-market losses on fair value of derivatives came in at Rs 784.3 crore. Singh said the ...
Q3 nos hit by falling Re, US turmoil: Ranbaxy  

05:17 PM | 31 October

Malvinder Mohan Singh, CEO and MD, Ranbaxy, said Q3 earnings have hit by currency movement and developments in the US. The company, he said, has seen ...
Daiichi acquires 52.5% in Ranbaxy  

03:36 PM | 20 October

Daiichi Sankyo has acquired a 52.5% stake in India’s largest pharmaceutical company Ranbaxy Labs, after the Ranbaxy board approved preference allotmen...
| 1 | 2 | 3

On Moneycontrol

  • Latest
  • Most Popular
Add to Watchist
close[x]
Have you invested in these stocks? You can track them better in your Portfolio
Edit Watchlist
Sanjay Dutt back in jail; with this, do you think justice has been served?
Yes
No

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window